The resurgence of measles after years of near elimination underscores an urgent need for novel therapeutic modalities. Measles, caused by a highly contagious respiratory virus, poses significant risk to individuals who cannot mount an adequate immune response, including pregnant women and the immunocompromised. The traditional live-virus measles vaccine, while highly effective in healthy individuals, is contraindicated for these at-risk groups. Monoclonal antibody therapy offers a promising alternative because it can provide passive immunity by directly neutralizing the virus, thereby offering immediate protection without relying on the host’s immune activation.

Preclinical investigations into the efficacy of these monoclonal antibodies have demonstrated potent neutralization of measles virus particles in various animal models. Although these data are pending publication, Dr. Ronald Moss, President and CEO of Saravir Biopharma, describes the results as very promising. The antibodies specifically target viral fusion proteins expressed on measles-infected cells and free virus particles, blocking the fusion process essential for viral entry and spread. By impeding this critical mechanism, the antibodies effectively prevent infection at the cellular level, which is a novel approach to measles management.

Saravir Biopharma, headquartered in Encinitas, California, was co-founded by Dr. Moss, an experienced physician-scientist with a track record of leading antiviral and vaccine development from fundamental research to advanced clinical trials. Saravir’s mission is to develop the first monoclonal antibody-based therapeutic against measles, addressing an urgent unmet clinical need. The collaboration with Vanderbilt leverages access to human monoclonal antibodies derived from natural human immune responses, providing a strong foundation for therapeutic success.

Dr. James Crowe Jr., director of the Vanderbilt Center for Antibody Therapeutics and a University Distinguished Professor of Pediatrics and Chemistry, has been instrumental in advancing monoclonal antibody research targeting a spectrum of viral pathogens. His laboratory’s expertise in isolating and characterizing neutralizing antibodies underpins this initiative. The antibodies developed demonstrate specificity toward measles virus fusion proteins, a critical viral envelope component responsible for initiating host cell entry. Such targeted therapy could revolutionize prophylactic and treatment strategies for measles.

Historically, the United States achieved near elimination of measles due to high vaccination coverage, but recent trends reveal an alarming increase in cases. The Centers for Disease Control and Prevention (CDC) reported 2,285 confirmed measles cases in 2025, with an additional 1,575 cases reported in the first quarter of 2026 alone. This resurgence is attributed largely to declining vaccine coverage and increasing vaccine hesitancy, which undermines herd immunity and facilitates viral transmission.

Monoclonal antibody therapy offers several advantages over existing vaccines in specific patient populations. Besides immediate action, antibodies can be administered to individuals contraindicated for vaccination, offering protective benefits without necessitating an active immune response. This approach is especially vital for pregnant women and immunocompromised patients, who are disproportionately susceptible to severe complications. By neutralizing the virus extracellularly and at the infected cell surface, these antibodies halt disease progression and prevent transmission.

The next phase in the development pipeline involves initiating human clinical trials to establish safety, dosage, and efficacy profiles. While traditional pharma development timelines are extensive, the accelerating spread of measles may enable regulatory agencies to fast-track these processes, expediting access to life-saving therapies. Saravir Biopharma, in partnership with Vanderbilt, is poised to navigate these clinical stages efficiently, aiming to deliver an effective monoclonal antibody therapy within a shortened timeframe.

Dr. Moss emphasized the determination of his team to advance these antibodies despite the inherent challenges. The long-predicted resurgence of measles outbreaks necessitates rapid and innovative countermeasures. With extensive expertise in antiviral drug development, Saravir’s leadership is well-suited to translate Vanderbilt’s scientific discoveries into clinically viable therapeutics aimed at curbing measles transmission and mitigating disease severity.

In summary, this collaboration represents a transformative approach to infectious disease therapeutics by combining cutting-edge antibody engineering with an acute public health need. The monoclonal antibodies developed at Vanderbilt, now being advanced by Saravir Biopharma, are poised to become a critical adjunct to vaccination programs, providing protection for vulnerable groups and potentially altering the landscape of measles prevention and treatment. As measles continues to threaten global health despite available vaccines, these innovative therapies could play a decisive role in future outbreak responses.

The scientific community and public health officials alike recognize the importance of this advancement as a potential game-changer in infectious disease control. By harnessing the precision of monoclonal antibodies, this therapeutic strategy offers hope for reducing the incidence and severity of measles worldwide. Continued research, rigorous clinical testing, and regulatory scrutiny will be essential to realize the full potential of this promising new treatment.

As research progresses, public awareness and support for antibody therapies will be crucial. These therapies may set a precedent for similar interventions for other viral infections, especially where traditional vaccination approaches face limitations due to immune system constraints or safety concerns. The development of anti-measles monoclonal antibodies thus represents a significant milestone in the broader field of antiviral therapeutics and immunology.

Subject of Research: Development of human monoclonal antibody therapy for measles treatment and prevention
Article Title: Vanderbilt Center for Antibody Therapeutics and Saravir Biopharma Collaborate to Develop Human Monoclonal Antibodies Targeting Measles Virus
News Publication Date: Not specified
Web References:
– Vanderbilt Center for Antibody Therapeutics: https://www.vumc.org/vcat/home
– Saravir Biopharma: http://www.saravir.com
– James Crowe Jr., MD: https://www.vumc.org/crowe-lab/person/james-crowe-md
Image Credits: Illustration by Elad Binshtein, PhD, senior scientist – cryo-EM in the Crowe lab, Vanderbilt Health © Elad Binshtein/Vanderbilt Health
Keywords: Measles, Monoclonal antibody therapy, Viral fusion proteins, Infectious diseases, Antiviral therapeutics, Immune-compromised patients, Vaccine alternatives

The core of this breakthrough lies in engineering the Marburg virus glycoprotein (GP), which plays an essential role in viral attachment and entry into host cells. Researchers have focused on stabilizing the prefusion conformation of the MARV GP ectodomain trimer—the structural state before the virus fuses with the host cell membrane. This prefusion state is crucial because it presents neutralizing epitopes recognized by antibodies, making it a prime target for vaccine design and immunotherapeutic intervention. By introducing targeted mutations, the team successfully enhanced the expression levels and thermal stability of the GP trimer, thereby increasing its immunogenicity in preclinical models.

The study’s most compelling revelation is the identification of a potent, fully human monoclonal antibody named MARV16. Unlike previously described antibodies, MARV16 demonstrates broad-spectrum neutralizing activity against all known Marburg virus strains, as well as against related filoviruses such as Ravn virus and Dehong virus. Remarkably, MARV16 exhibits a 40- to 100-fold increase in neutralization potency compared to earlier antibodies, setting a new benchmark in the fight against these deadly hemorrhagic viruses.

Functional analyses have established that MARV16 confers therapeutic protection in guinea pigs experimentally infected with MARV, highlighting its potential as a life-saving treatment. The antibody’s efficacy in this animal model underscores its promise for clinical development, especially considering the current lack of approved therapies for MARV infection in humans.

Delving into the structural basis for MARV16’s broad neutralizing capacity, the researchers employed cryo-electron microscopy to visualize the antibody bound to the prefusion Marburg GP. This high-resolution structure revealed that MARV16 specifically targets an epitope that spans both the GP1 and GP2 subunits, which are integral to receptor engagement and membrane fusion. By binding this site, MARV16 blocks the virus from attaching to its cellular receptor and prevents the dramatic conformational changes necessary for viral entry—a dual mechanism underscoring its exceptional neutralizing capability.

Moreover, the study unveiled the elaborate architecture of the Marburg virus GP glycan cap, a heavily glycosylated region that shields the receptor-binding site (RBS) from immune recognition. This glycan cap poses a formidable obstacle for antibody binding but shares architectural features with glycoproteins from distantly related filoviruses, suggesting conserved structural vulnerabilities that can be exploited therapeutically.

Interestingly, MARV16’s epitope partially overlaps with regions targeted by other previously identified receptor-binding site-directed antibodies. These findings indicate that MARV16 can bind simultaneously with these antibodies to the same viral glycoprotein, enabling the formation of potent antibody cocktails. Such combination therapies are significant because they require the virus to acquire multiple concurrent mutations to evade neutralization, thereby limiting the risk of resistance emerging during treatment.

The advancement in stabilizing the prefusion Marburg GP trimer vaccine antigen, coupled with the discovery of MARV16, represents a critical leap forward in both preventative and therapeutic strategies against Marburg virus disease. Stabilized GP trimers are anticipated to elicit robust immune responses, making them promising vaccine candidates, while MARV16 provides a blueprint for developing highly effective monoclonal antibody therapies with broad and potent activity.

These scientific accomplishments come at a crucial time when filovirus outbreaks continue to challenge global health infrastructure, particularly in regions with limited access to advanced medical care. The ability to generate vaccine candidates with enhanced stability and immunogenicity, alongside potent cross-reactive antibodies, may revolutionize the response to hemorrhagic fever outbreaks caused by MARV and related viruses.

Future research will be vital to translating these preclinical findings into safe and effective vaccines and antibody therapies that can be deployed in human populations. Clinical trials evaluating the safety profile, pharmacokinetics, and protective efficacy of MARV16 as a monoclonal antibody treatment are essential next steps. Simultaneously, optimizing the stabilized Marburg GP trimers as immunogens for vaccine development could foster durable immunity and potentially curb the spread of Marburg virus.

This work underscores the power of rational protein engineering and structural virology to reveal viral vulnerabilities and inform the design of next-generation countermeasures. It highlights a paradigm in which detailed molecular understanding of viral entry machinery directly informs the development of transformative vaccines and therapeutics capable of curtailing deadly viral diseases.

By harnessing advanced biotechnological approaches and leveraging human antibody repertoires, researchers are paving the way toward a future where outbreaks of Marburg virus—once incurable and devastating—can be prevented or effectively treated. This milestone provides hope not only for endemic regions but also for global preparedness against emerging infectious diseases from filoviruses.

As the scientific community continues building on these findings, the prospect of clinically available medical interventions against Marburg virus disease becomes increasingly tangible. This marks an era of optimism where innovative immunological tools stand to save countless lives from the grip of hemorrhagic fever viruses.

Subject of Research: Marburg virus neutralization, vaccine antigen engineering, monoclonal antibody therapeutics

Article Title: Potent neutralization of Marburg virus by a vaccine-elicited antibody

Article References:
Addetia, A., Perruzza, L., Sprouse, K. et al. Potent neutralization of Marburg virus by a vaccine-elicited antibody. Nature (2025). https://doi.org/10.1038/s41586-025-09868-1

Image Credits: AI Generated